Who are Trivalent OPV 4 week interval's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Euvichol-S Oral Cholera Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trivalent-opv-4-week-interval.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Trivalent OPV 4 week interval — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trivalent OPV 4 week interval (Trivalent OPV 4 week interval) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated oral vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated oral vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Trivalent OPV 4 week interval (Trivalent OPV 4 week interval) — International Centre for Diarrhoeal Disease Research, Bangladesh. Trivalent OPV provides immunization against three serotypes of poliovirus (types 1, 2, and 3) by inducing mucosal and systemic immune responses through oral administration of live attenuated virus.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trivalent OPV 4 week interval TARGET	Trivalent OPV 4 week interval	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Live attenuated oral vaccine
Euvichol-S Oral Cholera Vaccine	Euvichol-S Oral Cholera Vaccine	Albert B. Sabin Vaccine Institute	marketed	Live attenuated oral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated oral vaccine class)

Albert B. Sabin Vaccine Institute · 1 drug in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trivalent OPV 4 week interval — Competitive Intelligence Brief. https://druglandscape.com/ci/trivalent-opv-4-week-interval. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing